Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Br J Haematol. 2017 Jun 27;179(1):50–60. doi: 10.1111/bjh.14813

Figure 1.

Figure 1

Figure 1

A: Cumulative incidence of Relapse or Refractory disease in a cohort of patients with de novo diffuse large B cell lymphoma (DLBCL) treated with immunochemotherapy (IC).

B: Overall of survival from the time of relapse or refractoriness in DLBCL.